Glycosylated proteins, namely glycoproteins and proteoglycans (collectively called glycoconjugates), are indispensable in a variety of biological processes. The functions of many glycoconjugates are regulated by their interactions with another group of proteins known as lectins. In order to understand the biological functions of lectins and their glycosylated binding partners, one must obtain these proteins in pure form. The conventional protein purification methods often require long times, elaborate infrastructure, costly reagents, and large sample volumes. To minimize some of these problems, we recently developed and validated a new method termed capture and release (CaRe). This method is time‐saving, precise, inexpensive, and it needs a relatively small sample volume. In this approach, targets (lectins and glycoproteins) are captured in solution by multivalent ligands called target capturing agents (TCAs). The captured targets are then released and separated from their TCAs to obtain purified targets. Application of the CaRe method could play an important role in discovering new lectins and glycoconjugates. © 2020 Wiley Periodicals LLC.
Studying and quantifying the mechanics of blood clots is essential to better diagnosis and prognosis of, as well as therapy for, thromboembolic pathologies such as strokes, heart attacks, and pulmonary embolisms. Unfortunately, mechanically testing blood clots is complicated by their softness and fragility, thus making the use of classic mounting techniques, such as clamping, challenging. This is particularly true for mechanical testing under large deformation. Here, we describe protocols for creating in vitro blood clots and securely mounting these samples on mechanical test equipment. To this end, we line 3D‐printed molds with a hook‐and‐loop fabric that, after coagulation, provides a secure interface between the sample and device mount. In summary, our molding and mounting protocols are ideal for performing large‐deformation mechanical testing, with samples that can withstand substantial deformation without delaminating from the apparatus. © 2021 Wiley Periodicals LLC.
- NSF-PAR ID:
- 10276768
- Publisher / Repository:
- Wiley Blackwell (John Wiley & Sons)
- Date Published:
- Journal Name:
- Current Protocols
- Volume:
- 1
- Issue:
- 7
- ISSN:
- 2691-1299
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
more » « less
Abstract Basic Protocol 1 : Preparation of crude extracts containing the target proteins from soybean flourAlternate Protocol 1 : Preparation of crude extracts from Jack bean mealAlternate Protocol 2 : Preparation of crude extracts from the corms ofColocasia esculenta ,Xanthosoma sagittifolium , and from the bulbs ofAllium sativum Alternate Protocol 3 : Preparation ofEscherichia coli cell lysates containing human galectin‐3Alternate Protocol 4 : Preparation of crude extracts from chicken egg whites (source of ovalbumin)Basic Protocol 2 : Preparation of 2% (v/v) red blood cell suspensionBasic Protocol 3 : Detection of lectin activity of the crude extractsBasic Protocol 4 : Identification of multivalent inhibitors as target capturing agents by hemagglutination inhibition assaysBasic Protocol 5 : Testing the capturing abilities of target capturing agents by precipitation/turbidity assaysBasic Protocol 6 : Capturing of targets (lectins and glycoproteins) in the crude extracts by target capturing agents and separation of the target‐TCA complex from other components of the crude extractsBasic Protocol 7 : Releasing the captured targets (lectins and glycoproteins) by dissolving the complexBasic Protocol 8 : Separation of the targets (lectins and glycoproteins) from their respective target capturing agentsBasic Protocol 9 : Verification of the purity of the isolated targets (lectins or glycoproteins) -
more » « less
Abstract Nanobodies (nAbs) are recombinant antigen‐binding variable domain fragments obtained from heavy‐chain‐only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well‐established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.
This article was corrected on 26 June 2021. See the end of the full text for details.
Basic Protocol 1 : Total RNA isolation from camelid leukocytesBasic Protocol 2 : First‐strand cDNA synthesis; VHH and VHrepertoire PCRBasic Protocol 3 : Preparation of the phage display libraryBasic Protocol 4 : Panning of the phage display libraryBasic Protocol 5 : Small‐scale nAb expressionBasic Protocol 6 : Sequence analysis of selected nAb clonesBasic Protocol 7 : Nanobody validation as immunolabelsBasic Protocol 8 : Generation of nAb‐pEGFP mammalian expression constructsBasic Protocol 9 : Nanobody validation as intrabodiesSupport Protocol 1 : ELISA for llama serum testing, phage titer, and screening of selected clonesSupport Protocol 2 : Amplification of helper phage stockSupport Protocol 3 : nAb expression in amber suppressorE. coli bacterial strains -
more » « less
Abstract Articular cartilage is a multiphasic, anisotropic, and heterogeneous material. Although cartilage possesses excellent mechanical and biological properties, it can undergo mechanical damage, resulting in osteoarthritis. Thus, it is important to understand the microscale failure behavior of cartilage in both basic science and clinical contexts. Determining cartilage failure behavior and mechanisms provides insight for improving treatment strategies to delay osteoarthritis initiation or progression and can also enhance the value of cartilage as bioinspiration for material fabrication. To investigate microscale failure behavior, we developed a protocol to initiate fractures by applying a microindentation technique using a well‐defined tip geometry that creates localized cracks across a range of loading rates. The protocol includes extracting the tissue from the joint, preparing samples, and microfracture. Various aspects of the experiment, such as loading profile and solvent, can be adjusted to mimic physiological or pathological conditions and thereby further clarify phenomena underlying articular cartilage failure. © 2021 Wiley Periodicals LLC.
Basic Protocol 1 : Harvesting and dissection of the joint surfacesBasic Protocol 2 : Preparation of samples for microindentation and fatigue testingBasic Protocol 3 : Microfracture using microindentationBasic Protocol 4 : Crack propagation under cyclic loading -
more » « less
Abstract Glycosaminoglycans (GAGs) are linear polysaccharides found in a variety of organisms. GAGs contribute to biochemical pathway regulation, cell signaling, and disease progression. GAG sequence information is imperative for determining structure‐function relationships. Recent advances in electron‐activation techniques paired with high‐resolution mass spectrometry allow for full sequencing of GAG structures. Electron detachment dissociation (EDD) and negative electron transfer dissociation (NETD) are two electron‐activation methods that have been utilized for GAG characterization. Both methods produce an abundance of informative glycosidic and cross‐ring fragment ions without producing a high degree of sulfate decomposition. Here, we provide detailed protocols for using EDD and NETD to sequence GAG chains. In addition to protocols directly involving performing these MS/MS methods, protocols include sample preparation, method development, internal calibration, and data analysis. © 2021 Wiley Periodicals LLC.
This article was corrected on 27 July 2022. See the end of the full text for details.
Basic Protocol 1 : Preparation of glycosaminoglycan samplesBasic Protocol 2 : FTICR method developmentBasic Protocol 3 : Internal calibration with NaTFABasic Protocol 4 : Electron Detachment Dissociation (EDD) of GAG samplesBasic Protocol 5 : Negative electron transfer dissociation (NETD) of GAG samplesBasic Protocol 6 : Analysis of MS/MS data -
more » « less
Abstract Exosomes are 50‐ to 150‐nm‐diameter extracellular vesicles secreted by all mammalian cells except mature red blood cells and contribute to diverse physiological and pathological functions within the body. Many methods have been used to isolate and analyze exosomes, resulting in inconsistencies across experiments and raising questions about how to compare results obtained using different approaches. Questions have also been raised regarding the purity of the various preparations with regard to the sizes and types of vesicles and to the presence of lipoproteins. Thus, investigators often find it challenging to identify the optimal exosome isolation protocol for their experimental needs. Our laboratories have compared ultracentrifugation and commercial precipitation‐ and column‐based exosome isolation kits for exosome preparation. Here, we present protocols for exosome isolation using two of the most commonly used methods, ultracentrifugation and precipitation, followed by downstream analyses. We use NanoSight nanoparticle tracking analysis and flow cytometry (Cytek®) to determine exosome concentrations and sizes. Imaging flow cytometry can be utilized to both size exosomes and immunophenotype surface markers on exosomes (ImageStream®). High‐performance liquid chromatography followed by nano‐flow liquid chromatography–mass spectrometry (LCMS) of the exosome fractions can be used to determine the presence of lipoproteins, with LCMS able to provide a proteomic profile of the exosome preparations. We found that the precipitation method was six times faster and resulted in a ∼2.5‐fold higher concentration of exosomes per milliliter compared to ultracentrifugation. Both methods yielded extracellular vesicles in the size range of exosomes, and both preparations included apoproteins. © 2020 Wiley Periodicals LLC.
Basic Protocol 1 : Pre‐analytic fluid collection and processingBasic Protocol 2 : Exosome isolation by ultracentrifugationAlternate Protocol 1 : Exosome isolation by precipitationBasic Protocol 3 : Analysis of exosomes by NanoSight nanoparticle tracking analysisAlternate Protocol 2 : Analysis of exosomes by flow cytometry and imaging flow cytometryBasic Protocol 4 : Downstream analysis of exosomes using high‐performance liquid chromatographyBasic Protocol 5 : Downstream analysis of the exosome proteome using nano‐flow liquid chromatography–mass spectrometry
